Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARIEL4: rucaparib versus chemotherapy in BRCA-mutated recurrent ovarian, fallopian tube, or primary peritoneal cancer
MOH_2017-03-19_000121Phase 3Recruiting
- Sponsor
- Clovis Oncology
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rucaparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Clovis Oncology. Started Nov 2016; status: recruiting.
02
Drugs
rucaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on MOH_2017-03-19_000121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-19_000121.